STK11 and non-small cell lung carcinoma: Another recent study found that NSCLC patients with mutated serine/threonine kinase 11 (STK11) do not respond favorably to the combined treatment with immune checkpoint inhibitors against PD-L1 (durvalumab) and CTLA4 (tremelimumab).